Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Southern Colorado PC; Clinical Research Department
1161
mi
from 43215
Colorado Springs, CO
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Southern Colorado PC; Clinical Research Department
1161
mi
from 43215
Colorado Springs, CO
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Colorado Retina Associates
1174
mi
from 43215
Golden, CO
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Colorado Retina Associates
1174
mi
from 43215
Golden, CO
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Rand Eye
960
mi
from 43215
Deerfield Beach, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Rand Eye
960
mi
from 43215
Deerfield Beach, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
National Ophthalmic Research Institute
932
mi
from 43215
Fort Myers, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
National Ophthalmic Research Institute
932
mi
from 43215
Fort Myers, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Florida Eye Associates
832
mi
from 43215
Melbourne, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Florida Eye Associates
832
mi
from 43215
Melbourne, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Southern Vitreoretinal Assoc
659
mi
from 43215
Tallahassee, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Southern Vitreoretinal Assoc
659
mi
from 43215
Tallahassee, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Southeast Retina Center, P.C.
451
mi
from 43215
Augusta, GA
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Southeast Retina Center, P.C.
451
mi
from 43215
Augusta, GA
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Midwest Eye Institute
166
mi
from 43215
Indianapolis, IN
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Midwest Eye Institute
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Wolfe Eye Clinic
572
mi
from 43215
West Des Moines, IA
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Wolfe Eye Clinic
572
mi
from 43215
West Des Moines, IA
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
The Retina Care Center
340
mi
from 43215
Baltimore, MD
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
The Retina Care Center
340
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Vitreo Retinal Surgery
624
mi
from 43215
Minneapolis, MN
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Vitreo Retinal Surgery
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Sierra Eye Associates
1936
mi
from 43215
Reno, NV
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Sierra Eye Associates
1936
mi
from 43215
Reno, NV
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Eye Associates of New Mexico
mi
from 43215
Albuquerque, NM
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Eye Associates of New Mexico
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Vitreoretinal Consultants
492
mi
from 43215
Great Neck, NY
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Vitreoretinal Consultants
492
mi
from 43215
Great Neck, NY
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Opthalmic Consultants of LI
494
mi
from 43215
Lynbrook, NY
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Opthalmic Consultants of LI
494
mi
from 43215
Lynbrook, NY
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Char Eye Ear &Throat Assoc
353
mi
from 43215
Charlotte, NC
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Char Eye Ear &Throat Assoc
353
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Assoc. of Cleveland
130
mi
from 43215
Cleveland, OH
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Assoc. of Cleveland
130
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Oregon Retina, LLP
2055
mi
from 43215
Eugene, OR
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Oregon Retina, LLP
2055
mi
from 43215
Eugene, OR
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Northwest, PC
2026
mi
from 43215
Portland, OR
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Northwest, PC
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Charles Retina Institution
499
mi
from 43215
Germantown, TN
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Charles Retina Institution
499
mi
from 43215
Germantown, TN
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Texas Retina Associates
928
mi
from 43215
Arlington, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Texas Retina Associates
928
mi
from 43215
Arlington, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Austin Retina Associates
1064
mi
from 43215
Austin, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Austin Retina Associates
1064
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Research Center
1064
mi
from 43215
Austin, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Research Center
1064
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Utah
1513
mi
from 43215
Salt Lake City, UT
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Utah
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Vitreous Assoc of FL
842
mi
from 43215
Saint Petersburg, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Vitreous Assoc of FL
842
mi
from 43215
Saint Petersburg, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Southeastern Retina Associates Chattanooga
361
mi
from 43215
Chattanooga, TN
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Southeastern Retina Associates Chattanooga
361
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Res Institute of Texas
1068
mi
from 43215
Abilene, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Res Institute of Texas
1068
mi
from 43215
Abilene, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Strategic Clinical Research Group, LLC
999
mi
from 43215
Willow Park, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Strategic Clinical Research Group, LLC
999
mi
from 43215
Willow Park, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Mid Atlantic Retina - Wills Eye Hospital
425
mi
from 43215
Cherry Hill, NJ
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Mid Atlantic Retina - Wills Eye Hospital
425
mi
from 43215
Cherry Hill, NJ
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
491
mi
from 43215
Birmingham, AL
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
491
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
126
mi
from 43215
Cleveland, OH
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
126
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
1
mi
from 43215
Columbus, OH
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
508
mi
from 43215
Memphis, TN
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
508
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
mi
from 43215
Waterloo,
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
mi
from 43215
Waterloo,
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
991
mi
from 43215
Houston, TX
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
Objective, Prospective Measurement of Anterior Chamber Cell Grading Using Anterior Chamber Ocular Coherence Tomography
Status: Enrolling
Updated:  12/31/1969
Doctors Office Center
467
mi
from 43215
Newark, NJ
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
Objective, Prospective Measurement of Anterior Chamber Cell Grading Using Anterior Chamber Ocular Coherence Tomography
Status: Enrolling
Updated: 12/31/1969
Doctors Office Center
467
mi
from 43215
Newark, NJ
Click here to add this to my saved trials
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
446
mi
from 43215
Morrow, GA
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
446
mi
from 43215
Morrow, GA
Click here to add this to my saved trials
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
81
mi
from 43215
Mason, OH
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
81
mi
from 43215
Mason, OH
Click here to add this to my saved trials
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
508
mi
from 43215
Memphis, TN
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
508
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Golden Optometric Group
1965
mi
from 43215
Whittier, CA
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Golden Optometric Group
1965
mi
from 43215
Whittier, CA
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Edward S. Wygonik, OD
675
mi
from 43215
Jacksonville Beach, FL
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Edward S. Wygonik, OD
675
mi
from 43215
Jacksonville Beach, FL
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Dr. James Weber & Associates, PA
671
mi
from 43215
Jacksonville, FL
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Dr. James Weber & Associates, PA
671
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Sabal Eye Care
784
mi
from 43215
Longwood, FL
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Sabal Eye Care
784
mi
from 43215
Longwood, FL
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Maitland Vision Center
789
mi
from 43215
Maitland, FL
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Maitland Vision Center
789
mi
from 43215
Maitland, FL
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Optometry
193
mi
from 43215
Bloomington, IN
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Optometry
193
mi
from 43215
Bloomington, IN
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Kannarr Eye Care LLC
653
mi
from 43215
Pittsburg, KA
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Kannarr Eye Care LLC
653
mi
from 43215
Pittsburg, KA
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
ABQ Eye Care
1326
mi
from 43215
Albuquerque, NM
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
ABQ Eye Care
1326
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Sacco Eye Group
391
mi
from 43215
Vestal, NY
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Sacco Eye Group
391
mi
from 43215
Vestal, NY
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
ProCare Vision Centers
29
mi
from 43215
Granville, OH
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
ProCare Vision Centers
29
mi
from 43215
Granville, OH
Click here to add this to my saved trials